Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2764-2771

  Ingvar, Åsa ^a   Smedby, Karin Ekström ^b   Lindelöf, Bernt ^b   Fernberg, Pia ^a   Bellocco, Rino ^a,c   Tufveson, Gunnar ^d   Höglund, Petter ^a   Adami, Johanna ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

case control study; cutaneous squamous cell carcinoma; immunosuppressive treatment; organ transplantation

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA A ANTIGEN; HLA B27 ANTIGEN; HLA DR ANTIGEN; HYDROCORTISONE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; GRAFT REJECTION; HEART TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; POPULATION BASED CASE CONTROL STUDY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SQUAMOUS CELL CARCINOMA; SWEDEN; TREATMENT DURATION; AGED; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; CHEMICALLY INDUCED; IMMUNOLOGY; MIDDLE AGED; RISK FACTOR; SKIN NEOPLASMS; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; SKIN NEOPLASMS; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 77954765640     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp425     Document Type: Article

References (30)

1. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. IntJCancer 1995; 60: 183
2. Adami J, Gabel H, Lindelof B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221
3. Gruber SA, Gillingham K, Sothern RB et al. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994; 8: 388
4. Ramsay HM, Fryer AA, Hawley CM et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49: 397
5. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000;143:513
6. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990; 49: 506
7. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40(Pt 1): 177
8. Hiesse C, Rieu P, Kriaa F et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997; 29: 831
9. Kinlen LJ, Sheil AG, Peto J et al. Collaborative United Kingdom- Australasian study of cancer in patients treated with immunosuppres- sive drugs. Br Med J 1979; 2: 1461
10. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term im- munosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623
11. Kelly GE, Meikle W, Sheil AG. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44: 429
12. O'Donovan P, Perrett CM, Zhang X etal. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871
13. Bouwes Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996; 61: 715
14. Naldi L, Fortina AB, Lovati S et al. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. Transplantation 2000; 70: 1479
15. Sheil AG, Disney AP, Mathew TH et al. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA. Transplant Proc 1991; 23(Pt 2): 1111
16. Glover MT, Deeks JJ, Raftery MJ et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997;349:398
17. Montagnino G, Lorca E, Tarantino A et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996; 10: 461
18. Fortina AB, Piaserico S, Caforio AL et al. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004; 140: 1079
19. Bouwes Bavinck JN, Vermeer BJ, Van Der Woude FJ et al. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991; 325: 843
20. Ramsay HM, Fryer AA, Reece S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167
21. National Board of Health and Welfare, Centre for Epidemiology. In- patient diseases in Sweden 1987-2006. Cancer incidence in Sweden 2006, 2007.
22. Nilsson AC, Spetz CL, Carsjo K et al. Reliability of the hospital registry. The diagnostic data are better than their reputation. Lakar- tidningen 1994; 91: 598
23. Wassberg C, Thorn M, Johansson AM et al. Increasing incidence rates of squamous cell carcinoma of the skin in Sweden. Acta Derm Venereol 2001; 81: 268
24. Ardizzone S, Bianchi Porro G. Comparative tolerability of therapies for ulcerative colitis. Drug Saf 2002; 25: 561
25. Hosmer D, Lemeshow S. Model building strategies. Applied Logistic Regression. Amherst: Wiley, 1989, Chapter 4.
26. Karagas MR, Cushing GL Jr., Greenberg ER et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 683
27. Sorensen HT, Mellemkjaer L, Nielsen GL et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96: 709
28. Yuan B, Wang Y. Mutagenic and cytotoxic properties of 6- thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid. JBiol Chem 2008; 283: 23665
29. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530
30. Lindelof B, Granath F, Dal H et al. Sun habits in kidney transplant recipients with skin cancer: a case-control study of possible causative factors. Acta Derm Venereol 2003; 83: 189